Repurposed Drugs Show Promise for Intellectual Disability Linked to NCOR Mutations
New Research Explores Treatment for NCOR-Related Cognitive Impairment
Recent scientific advances have shed light on potential treatments for intellectual disability associated with mutations in nuclear receptor corepressor genes (NCOR1/2). These genes play a crucial role in regulating the activity of methyl-CpG binding protein 2 (MECP2), which is linked to autism spectrum disorders and intellectual disability. A study published ahead of print in Advanced Science investigated how heterozygous mutations in NCOR1 affect cognitive functions and explored existing drugs that might alleviate related symptoms.
Key Findings from Mouse Models
Researchers developed a knock-in mouse model carrying a heterozygous NCOR1 mutation (c.2182+2T>G) identified in a pediatric patient. These NCOR1KI/+ mice exhibited behaviors reminiscent of autism and intellectual disability, including social avoidance, repetitive actions, and memory deficits. These symptoms mirrored those seen in mice with one copy of NCOR1 inactivated, indicating that even partial loss of NCOR1 function (haploinsufficiency) can impair cognition.
Molecular Insights into Cognitive Dysfunction
Single-nucleus RNA sequencing of hypothalamic GABAergic neurons from NCOR1KI/+ mice revealed elevated levels of neuregulins (Nrg1 and Nrg3) and decreased expression of the GABA receptor subunit Gabra2. Laboratory experiments showed that overexpressing Nrg1 in cultured neurons was sufficient to reduce Gabra2 levels. Further investigation demonstrated that spironolactone, a drug known to antagonize neuregulin signaling, prevented Gabra2 downregulation caused by full-length NRG1. However, spironolactone did not affect downregulation induced by the NRG1 intracellular domain, suggesting that a noncanonical signaling pathway is involved in the process triggered by NCOR1 loss-of-function.
Repurposing FDA-Approved Drugs to Improve Cognition
Importantly, treatment with spironolactone and allopregnanolone—a positive modulator of GABA-A receptors and also FDA-approved—ameliorated cognitive deficits in the NCOR1KI/+ mouse model. Extending these findings to humans, spironolactone improved learning outcomes in a patient with a pathogenic MECP2 mutation associated with autism.
Implications for Families and Future Research
This study provides a mechanistic understanding of how NCOR mutations may contribute to intellectual disability and offers preliminary evidence supporting the use of existing medications to target these pathways. While these findings are promising, further clinical trials are necessary to confirm safety and efficacy in broader patient populations. Families affected by NCOR-related cognitive disorders may find hope in these developments, but should consult healthcare professionals before considering any treatment changes.
Limitations and Cautions
Though the mouse model recapitulates key aspects of the human condition, animal studies do not always predict human outcomes. The exact pathways by which NCOR1 mutations disrupt brain function remain complex, and the effectiveness of spironolactone and allopregnanolone in diverse genetic backgrounds requires more research. Additionally, the improvement seen in a single patient with a MECP2 mutation is anecdotal and needs validation in controlled studies.
For a detailed review of the research, see the original publication: Drug Repurposing for Treating NCOR-Related Intellectual Disability.
Download the images in this article
